The predominance of moderate-to-severe AD (per the MMSE and GDS) aligns with the high use of memantine and combined therapies (e.g., memantine + cholinesterase inhibitors), which are guideline-recommended for advanced stages [30]. The gene discussed is BCHE; the disease is Alzheimer disease.